Dr. Vadim Jucaud’s laboratory at the Terasaki Institute has achieved a significant milestone with the development of a vascularized liver tissueoid-on-a-chip (LToC). This innovative platform mimics crucial structural, functional, and immunological characteristics of human liver tissue, offering a powerful tool for studying liver regeneration and immune-mediated allograft rejection in a system that closely resembles human physiology.
The Challenge of Liver Transplantation
Liver transplantation is the foremost treatment option for individuals suffering from end-stage liver disease. However, a comprehensive understanding of transplant rejection and tissue regeneration has been stymied by the absence of experimental models that accurately replicate the complex architecture and immune dynamics of human liver. Traditional culture systems often fall short, failing to provide the multicellular organization, vascular complexity, and dynamic immune responses that are critical to determining transplant outcomes, thereby limiting their applicability in translational research.
Engineering the Liver Tissueoid
To overcome these obstacles, Dr. Jucaud’s team has engineered a vascularized liver tissueoid using donor-matched human hepatic progenitor cells and intrahepatic portal vein endothelial cells. The creation process involves dynamic perfusion culture, where, within just a week, the tissueoid begins to self-assemble into a perfusable microvascular network. Over a 49-day culture period, this structure matures into a functional liver-like tissueoid.
The research team has successfully demonstrated that this platform sustains tissue viability, maintains vascular integrity, and supports active hepatic functions. Key indicators of liver function, such as the secretion of albumin, urea, and hepatocyte growth factor, were consistently observed. The mature tissueoid comprises a variety of liver-relevant cell populations, including hepatocytes, cholangiocytes, Kupffer cells, stellate cells, and endothelial cells, effectively reflecting the cellular diversity found in native human liver tissue.
Modeling Immune-Mediated Rejection
The LToC platform was further utilized to investigate immune-mediated allograft rejection by perfusing the mature tissueoid with allogeneic T cells. This interaction triggered hallmark features of cellular rejection, including a decrease in tissue viability, endothelial disruption, and a loss of hepatic markers. Additionally, the tissueoid exhibited increased expressions of HLA-I and a robust pro-inflammatory cytokine response. Notable elevations in cytokines such as IL-6, TNF-α, and IFN-γ were observed, mirroring immune activation patterns typically seen in clinical transplant rejections.
A New Era in Transplant Biology
Dr. Abdul Rahim Chethikkattuveli Salih, the first author of the study, emphasized the significance of this research in understanding liver regeneration and immune responses. Dr. Jucaud, Principal Investigator and Assistant Professor at the Terasaki Institute, added that integrating functional vasculature and multiple liver cell types into a single platform allows for more physiologically relevant studies of transplant biology. This innovative approach may facilitate the evaluation of immunosuppressive drugs and promote personalized strategies for liver transplantation.
Continuing a Legacy
The work conducted at the Terasaki Institute pays homage to the legacy of Dr. Paul I. Terasaki, a pioneer in organ transplantation research. His vision emphasized that innovation in transplantation should always prioritize improving patients’ lives. Dr. Jucaud expressed a personal commitment to this vision, as he was one of the last doctoral scholars trained by Dr. Terasaki. He believes that advancing translational science that bridges engineering, immunology, and transplantation is a tribute to Terasaki’s lasting impact on the field.
Future Directions
As the Terasaki Institute continues its mission to enhance patient-centered technologies, the vascularized liver tissueoid-on-a-chip stands as a testament to the potential of innovative research. By providing a more accurate model for studying liver function and rejection, this platform opens up new avenues for improving transplant outcomes and patient care.
- Key Takeaways:
- The LToC mimics human liver features, enhancing the study of liver biology.
- It successfully models immune-mediated allograft rejection in vitro.
- The research holds promise for evaluating immunosuppressive therapies and personalized transplant strategies.
This groundbreaking work not only represents a leap forward in our understanding of liver transplantation but also paves the way for future innovations that can significantly improve the quality of life for transplant patients.
Read more → www.news-medical.net